KMT2A and breast cancer: To assess the effects of combined PI3K/MLL1 inhibition on cell growth, the PI3K-activated (PIK3CAE545K-mutant), HR+ breast cancer cell line MCF7 was treated with the p110α-selective PI3K inhibitor alpelisib, the MLL1 inhibitor MI-503, or the combination.